Literature DB >> 13273488

Triazenes as inhibitors of mouse sarcoma 180.

D A CLARKE, R K BARCLAY, C C STOCK, C S RONDESTVEDT.   

Abstract

Entities:  

Keywords:  SARCOMA/experimental

Mesh：

Substances：

Year:  1955        PMID： 13273488     DOI： 10.3181/00379727-90-22073

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN： 0037-9727


× No keyword cloud information.
  7 in total

1.  AXONAL LESIONS AND WALTZING SYNDROME AFTER IDPN ADMINISTRATION IN RATS. WITH A CONCEPT--"AXOSTASIS".

Authors:  S M CHOU; H A HARTMANN
Journal:  Acta Neuropathol       Date:  1964-05-05       Impact factor: 17.088

Review 2.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  [Differing carcinogenic activity in BD-rats of 1-phenyl- and 1-(pyridyl-3)-3,3-diethyltriazene after single doses on 1., 10. or 30. day of life (author's transl)].

Authors:  S Ivankovic; R Port; R Preussmann
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1976-08-30

4.  Comparative carcinogenicity of ring-halogenated 3-methyl-1-phenyltriazenes and their 3,3-dimethyl analogs at equimolar dose levels in male Sprague-Dawley rats.

Authors:  M R Berger; G F Kolar
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

5.  Microsomal mediated metabolism of dialkylaryltriazenes. II. Isolation and identification of metabolites of 3,3-dimethyl-1-phenyltriazene.

Authors:  B L Pool
Journal:  J Cancer Res Clin Oncol       Date:  1979-04-12       Impact factor: 4.553

6.  Microsomal mediated metabolism of dialkylaryltriazenes. I. Demethylation of ring halogenated 3,3-dimethyl-1-phenyltriazenes.

Authors:  B L Pool
Journal:  J Cancer Res Clin Oncol       Date:  1979-04-12       Impact factor: 4.553

Review 7.  Temozolomide and Other Alkylating Agents in Glioblastoma Therapy.

Authors:  Hannah Strobel; Tim Baisch; Rahel Fitzel; Katharina Schilberg; Markus D Siegelin; Georg Karpel-Massler; Klaus-Michael Debatin; Mike-Andrew Westhoff
Journal:  Biomedicines       Date:  2019-09-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.